Back to search results

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer · Hepatocellular Carcinoma · Osteosarcoma · Epithelial Ovarian Cancer · Gastric Cancer · Non-small Cell Lung Cancer · Malignant Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • HonorHealth Research Institute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Patricia Shannon) · clinicaltrials@honorhealth.com · 480-323-1364
    Contact: Principal Investigator (Justin Moser, MD)

  • UC San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Natalia Ortuno) · nortuno@health.ucsd.edu · 858-246-2073
    Contact: Principal Investigator (Sandip Patel, MD)

  • Stanford University, Stanford, California, United States

    Contact: Study coordinator (Mary Herrera) · ccto-office@stanford.edu · 650-723-0622
    Contact: Principal Investigator (Oliver Dorigo, MD)
Study leads

  • Oliver Dorigo, MD

    Principal Investigator

    Stanford University

View source on ClinicalTrials.gov(opens in a new tab)